Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 121.58 -0.01 (-0.01%) Market Cap: 7.35 Bil Enterprise Value: 10.93 Bil PE Ratio: 17.12 PB Ratio: 1.76 GF Score: 85/100

Q4 2020 Jazz Pharmaceuticals PLC Earnings Call Transcript

Feb 23, 2021 / 09:30PM GMT
Release Date Price: $157.47 (-2.60%)
Operator

Hello, and welcome to the Jazz Pharmaceuticals Full Year and Fourth Quarter 2020 Financial Results Earnings Conference Call.

Following an introduction from the company, we will open the call for questions. I will now turn the call over to Andrea Flynn, Head of Investor Relations at Jazz Pharmaceuticals. You may begin.

Andrea N. Flynn
Jazz Pharmaceuticals plc - VP & Head of IR

Thank you. And thanks, everyone, joining the call. Today, we reported our fourth quarter and full year 2020 financial results and provided our financial guidance for 2021.

The press release and the slide presentation accompanying this call are available on the Investors section of our website. On the call today are Bruce Cozadd, CEO; Renee Gala, CFO; Dan Swisher, President; and Rob Iannone, Executive Vice President, R&D and Chief Medical Officer. Joining the Q&A are Kim Sablich, Executive Vice President and General Manager of North America; Phil Jochelson, Neuroscience Therapeutic Head; Anne Borgman, Hematology and Oncology therapeutic Head; Sam Pearce,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot